Stockholm Fashion District Hosts Fashion Week Trade Where Swedish Initiatives Are Paving the Way for a Bright New Future
14.8.2024 15:33:00 EEST | Business Wire | Press release
Stockholm Fashion District is revolutionizing the fashion industry by offering a vibrant platform for designers, creatives and buyers to connect. Unlike traditional trade platforms that occur just twice a year, Stockholm Fashion District hosts multiple trade shows annually - pushing the boundaries of industry conventions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240813925340/en/
Catwalk on the Grand Opening of Fashion Week Trade, 12-16 August 2024 (Photo: Business Wire)
This innovative approach allows creatives in the industry to connect, inspire and gain valuable market exposure, all under the same roof.
"The fashion industry is ever changing, therefore initiatives in trade conventions are crucial to reflect the current landscape and its eager pioneers" says Helena Walker, CEO Stockholm Fashion District
During this Fashion Week Trade, 12-16 August, Stockholm Fashion District opens its doors to one of the biggest trade events of the year. By incorporating 700 fashion brands, ranging from mid-market to premium, the event seamlessly blends different brands showcasing fashion, shoes and accessories.
With its purpose of bringing people together, the event will celebrate creativity and innovation by having fashion enthusiasts and professionals attending from all around the world. Relationships and businesses will grow.
"The world around us is definitely very challenging for our industry. Cooperation, flexibility, and transition are the way to the future, and we are a reliable player and meeting place for the industry. Together we create energy to find new opportunities." says Helena Walker, CEO Stockholm Fashion District
The fashion industry in Sweden is a significant contributor to the country's economy, generating a revenue of 173 billion SEK and employing around 40,000 people. Sweden is known for its emphasis on innovation, entrepreneurship, sustainability, and creativity - values that are reflected in the fashion industry.
Beyond the conventional twice-a-year fashion trade convention, Stockholm Fashion District is providing a year-round platform for designers, creatives and buyers to connect. Linking Swedish fashion enterprises to the global market, the area hosts 22 yearly sales-focused events in addition to its 143 showrooms that are open year-round. Along with collaborative opportunities and training sessions, Trade Partners Sweden supports with legal, logistical, and sales expertise. The organization supports fashion professionals all year round.
Fashion Week Trade is taking place between 12–16 August in Stockholm
Link to the program here
Link to the brand list here
For more information about the Swedish fashion industry, read the Fashion Transformation Report here.
ABOUT:
Stockholm Fashion District (SFD)
https://www.stockholmfash iondistrict.se
Trade Partners Sweden (TPS)
https://www.tradepartnerssweden.se/
Trade Partners Sweden is a member organization representing Swedish agents, suppliers, and distributors in fashion, shoes, and textiles. They are the founders of Stockholm Fashion District, a company that serves as the physical meeting place for the industry in Sweden and hosts events including Fashion Week Trade.
PRESS IMAGES:
Click here
View source version on businesswire.com: https://www.businesswire.com/news/home/20240813925340/en/
Contacts
PRESS CONTACT:
Linda Ekstrom, Head of Marketing & Communications
linda.ekstrom@tradepartners.se, - linda.ekstrom@tradepartners.se +46 73 525 99
53
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom